FIGURE 7.

Concentration of SGL5213 in the feces and effect on TPL activity. (a) The concentration of SGL5213 in the feces was measured by LC/MS/MS. Cont: control group (n = 8); RF; renal failure group (n = 6); RF treated with SGL5213 (10 mg/kg/day) group (n = 8–9 each). Data were mean ± SEM. (b) Effect of SGL5213 on TPL activity. One millimolar of the specific TPL inhibitor 2‐aza‐tyrosine, SGL5213, and canagliflozin (SGLT2/1 inhibitor) significantly and comparably inhibited the TPL activity. At 300 μM, 2‐aza‐tyrosine (2‐AZA) still completely and SGL5213 partly inhibited TPL activity. Data were mean ± SEM. Statistical analyses were performed using a Dunnett's test. *p < 0.05 was treated as statistically significant